GlassScriptPhysician profile
Pady Vang
NPI 1538799580
$2,967.69
in general payments reported to CMS, 2019-2025
43 companies · $30.79 in 2025
The $30.79 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,374 · 2022: $336 · 2023: $152 · 2024: $74.53 · 2025: $30.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $160 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $159.66 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $213.92 | 2021-2022 | |
| Astellas Pharma US INC | $183.75 | 2021-2022 | |
| Daiichi Sankyo INC. | $183.63 | 2021-2024 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $152.94 | 2021 | |
| Incyte Corporation | $143.08 | 2021 | |
| Karyopharm Therapeutics INC. | $142.99 | 2021 | |
| Glaxosmithkline, LLC. | $126.45 | 2021 | |
| Lilly USA, LLC | $109.86 | 2022 | |
| Kite Pharma, INC. | $107.42 | 2021 | |
| Merck Sharp & Dohme LLC | $106.09 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.66 | 2021 | |
| Janssen Biotech, INC. | $98.00 | 2023 | Imbruvica |
| Eisai INC. | $96.68 | 2021 | |
| Amgen INC. | $91.34 | 2021 | |
| Seagen INC. | $87.10 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pady Vang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.